Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome

Current Opinion in Rheumatology

Volumn 12, Issue 2, 2000, Pages 113-123

  Buskila, Dan ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DISABILITY; DISEASE CLASSIFICATION; FIBROMYALGIA; HUMAN; MYOFASCIAL PAIN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ADULT; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HUMANS; MYOFASCIAL PAIN SYNDROMES;

EID: 0034018295     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200003000-00005     Document Type: Review

References (84)

1. Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Franco-Marina F: Prevalence of fibromyalgia in children: a clinical study of Mexican children. J Rheumatol 1998, 25:2009-2014.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al.: The American College of Rheumatology 1990 criteria for the classification of FM: report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
3. Buskila D, Press J, Gedalia A, Klein M, Neumann L, Boehm R, Sukenik S: Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol 1993, 20:368-370.
4. Escalante A, Fishbach M: Musculoskeletal manifestations, pain, and quality of life in Persian Gulf War veterans referred for rheumatologic evaluation. J Rheumatol 1998, 25:2228-2235. No specific rheumatic diagnosis is characteristic of Gulf War veterans with unexplained illness referred to a rheumatology clinic. However, pain is common and widespread in these patients, and their health-related quality of life is poor.
5. Verhaak PFM, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM: Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998, 77:231-239.
6. Gamez-Nava JL, Gonzalez-Lopez L, Davis P, Suarez-Almazor ME: Referral and diagnosis of common rheumatic diseases by primary care physicians. Br J Rheumatol 1998, 37:1215-1219.
7. Buskila D, Neumann L, Sibirski D, Shvartzman P: Awareness of diagnostic and clinical features of fibromyalgia among family physicians. Fam Practice 1997, 14:238-241.
8. White KP, Harth M, Speechley M, Ostbye T: Testing an instrument to screen for fibromyalgia syndrome in general population studies: the London fibromyalgia epidemiology study screening questionnaire. J Rheumatol 1999, 26:880-884.
9. Hapidou EG, Rollman GB: Menstrual cycle modulation of tender points. Pain 1998, 77:151-161. Increased tenderness was demonstrated in the postmenstrual phase of the cycle compared with the intermenstrual phase in normally cycling women but not in users of oral contraceptives.
10. Smythe HA, Lee D, Rush P, Buskila D: Tender shins and steroid therapy. J Rheumatol 1991, 18:1568-1572.
11. Buskila D, Schleifer E, Odes HS, Neumann L: Increased non-articular tenderness in patients on steroid therapy. European J Pain 1998, 2:261-266.
12. Wolfe F: "Silicone related symptoms" are common in patients with fibromyalgia: no evidence for a new disease. J Rheumatol 1999, 26:1172-1175.
13. Rea T, Russo J, Katon W, Ashley RL, Buchwald D: A prospective study of tender points and fibromyalgia during and after an acute viral infection. Arch Intern Med 1999, 159:865-870. A prospective population-based study demonstrating that although a significant proportion of subjects infected acutely by infectious mononucleosis have tender points and pain at presentation, persistent FM infrequently follows acute infectious mononucleosis.
14. Yavuz S, Fresko I, Lamuryudan V, Yurdakul S, Yazici H: Fibromyalgia in Behçet's syndrome. J Rheumatol 1998, 25:2219-2220.
15. Grafe A, Wollina U, Tebbe B, Sprott H, Uhlemann C, Hein G: Fibromyalgia in lupus erythematosus. Acta Derm Venereol (Stockh) 1999, 79:62-64.
16. Handa R, Aggarwal P, Wali JP, Wig N, Dwivedi SN: Fibromyalgia in Indian patients with SLE. Lupus 1998, 7:475-478.
17. Buskila D, Odes LR, Neumann L, Odes HS: Fibromyalgia in inflammatory bowel disease. J Rheumatol 1999, 26:1167-1171. FM was common in IBD, particularly CD. The increased tenderness in CD may suggest a disease-specific effect.
18. Yunus MB: Psychological aspects of fibromyalgia syndrome: a component of the dysfunctional syndrome. Bailliers Clin Rheumatol 1994, 8:811-837.
19. Sprott H, Bradley LA, Oh SJ, Wintersberger W, Alarcon GS, Mussell HG, et al.: Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. Arthritis Rheum 1998, 41:1689-1694. 5-HT and neuropeptides are not produced in the muscle of patients with FM and do not appear to be involved in the peripheral induction of pain in this disorder.
20. Maes M, Libbrecht I, Van Hunsel F, Lin AH, Bonaccorso S, Goossens F, et al.: Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Psychol Med 1998, 28:957-965.
21. Cardenal A, Masuda I, Ono W, Haas AL, Ryan LM, Trotter D, et al.: Serum nucleotide pyrophosphohydrolase activity: elevated levels in osteoarthritis, calcium pyrophosphate crystal deposition disease, scleroderma, and fibromyalgia. J Rheumatol 1998, 25:2175-2180.
22. Wilson RB, Gluck OS, Tesser JRP, Rice JC, Meyer A, Bridges AJ: Antipolymer antibody reactivity in a subset of patients with fibromyalgia correlates with severity. J Rheumatol 1999, 26:402-407. Production of anti-polymer antibodies is associated with a subset of patients with FM.
23. Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S: Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999, 26:408-412. This preliminary study revealed a possible linkage of FM to the HLA region. These results require independent confirmation by other studies.
24. Older SA, Battafarano DF, Danning CL, Ward JA, Grady EP, Derman S, et al.: The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects. Correlations with insulin-like growth factor I. J Rheumatol 1998, 25:1180-1186.
25. Macfarlane GJ, Morris S, Hunt IM, Benjamin S, McBeth J, Papageorgiou AC et al.: Chronic widespread pain in the community: The influence of psychological symptoms and mental disorder on health care seeking behavior. J Rheumatol 1999, 26:413-419. Psychological distress is associated with chronic widespread pain in addition to any effect on whether consultation is sought for symptoms.
26. Sperber AD, Carmel S, Atzmon Y, Weisberg I, Shalit Y, Neumann L, Fich A, Buskila D: The sense of coherence index and the irritable bowel syndrome. A cross-sectional comparison among irritable bowel syndrome patients with and without coexisting fibromyalgia, irritable bowel syndrome nonpatients, and controls. Scand J Gastroenterol 1999, 34:259-263.
27. Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L, et al.: Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999, 40:57-63. This multicenter study demonstrated that patients with FM exhibited marked functional impairment, high levels of some lifetime and current psychiatric disorders, and significant current psychological distress.
28. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL: Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999, 106:534-543. Patients with FM were found to have an impaired ability to activate the hypothalamic-pituitary portion of the hypothalamic-pituitary-adrenal axis as well as the sympathoadrenal system, leading to reduced corticotropin and epinephrine responses to hypoglycemia.
29. Wikner J, Hirsch U, Wetterberg L, Rojdmark S: Fibromyalgia: a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol 1998, 49:179-183.
30. Press J, Phillip M, Neumann L, Barak R, Segev Y, Abu-Shakra M, Buskila D: Normal melatonin levels in patients with fibromyatgia syndrome. J Rheumatol 1998, 25:551-555.
31. Webb SM: Fibromyalgia and melatonin: are they related? Clin Endocrinol 1998, 49:161-162.
32. Goldenberg DL: Fibromyalgia syndrome a decade later: what have we learned? Arch Intern Med 1999, 159:777-785. This excellent review summarizes major issues in FM, including diagnostic utility of FM, psychiatric and central nervous system factors, therapy and outcome, and compensation and disability.
33. White KP, Speechley M, Harth M, Ostbye T: Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario. Arthritis Rheum 1999, 42:76-83. A study confirming that FM, more than chronic widespread pain alone, is a disabling illness.
34. Grossi G, Scares JJF, Angesleva J, Perski A: Psychosocial correlates of long-term sick-leave among patients with musculoskeletal pain. Pain 1999, 80:607-619.
35. Abu-Shakra M, Mader R, Langevitz P, Friger M, Codish S, Neumann L, Buskila D: Quality of life in systemic lupus erythematosus: A controlled study. J Rheumatol 1999, 26:306-309.
36. Scharf MB, Hauck M, Stover R, McDannold M, Berkowitz D: Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol 1998, 25:1986-1990.
37. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P: A randomized double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998, 37:1279-1286.
38. Berman BM, Ezzo J, Hadhazy V, Swyers P: Is acupuncture effective in the treatment of fibromyalgia? J Fam Prac 1999, 48:213-218.
39. Ambrogio N, Cuttiford J, Lineker S, Li L: A comparison of three types of neck support in fibromyalgia patients. Arthritis Care Res 1998, 11:405-410.
40. Mason LW, Goolkasian P, McCain GA: Evaluation of a multimodal treatment program for fibromyalgia. J Behavioral Med 1998, 21:163-178.
41. Morley S, Eccleston C, Wiliams A: Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 1999, 80:1-13. A useful review and meta-analysis of 25 randomized controlled trials providing good evidence for the effectiveness of cognitive behavioural therapy and behaviour therapy for chronic pain in adults.
42. Sandstrom MJ, Keefe FJ: Self-management of fibromyalgia: the role of formal coping skills training and physical exercise training programs. Arthritis Care Research 1998, 11:432-447.
43. Mikkelson M: One year outcome of preadolescents with flbromyalgia. J Rheumatol 1999, 26:674-682. This study supports a previous one, in which FM in children had a good outcome. However, fluctuation of pain symptoms in children might partly explain the outcome. Children with persistent FM showed persistent disability with a number of distress symptoms.
44. Buskila D, Neumann L, Hershman E, Gedalia A, Press J, Sukenik S: Fibromyalgia syndrome in children: an outcome study. J Rheumatol 1995, 22:525-528.
45. Steele L, Dobbins JG, Fukuda K, Reyes M, Randall B, Koppelman M, et al.: The epidemiology of chronic fatigue in San Francisco. Am J Med 1998, 105(3A):83S-90S. Conditions associated with unexplained chronic fatigue occurred in all sociodemographic groups in San Francisco, but appeared to be most prevalent among women, persons with lower income, and some racial minorities.
46. Kawakami N, Iwata N, Fujihara S, Kitamura T: Prevalence of chronic fatigue syndrome in a community population in Japan. Tohoku J Exp Med 1998, 186:33-41.
47. Jason LA, Wagner L, Rosenthal S, Goodlatte J, Lipkin D, Papernik M, et al.: Estimating the prevalence of chronic fatigue syndrome among nurses. Am J Med 1998, 105(3A):91S-93S.
48. Lange G, Wang S, De Luca J, Natelson BH: Neuroimaging in chronic fatigue syndrome. Am J Med 1998, 105(3A):50S-53S.
49. Tirelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, et al.: Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med 1998, 105(3A):54S-58S.
50. Stewart JM, Gewitz MH, Weldon A, Arlievsky N, Li K, Munoz J: Orthostatic intolerance in adolescent chronic fatigue syndrome. Pediatrics 1999, 103:116-121.
51. Stewart J, Weldon A, Arlievsky N, Li K, Munoz J: Neurally mediated hypotension and autonomic dysfunction measured by heart rate variability during head-up tilt testing in children with chronic fatigue syndrome. Clin Auton Res 1998, 8:221-230.
52. La Manca JJ, Peckerman A, Walker J, Kesil W, Cook S, Taylor A, et al.: Cardiovascular response during head-up tilt in chronic fatigue syndrome. Clin Physiol 1999, 19:111-120.
53. Becker PD, Dendale P, De Meirleir K, Campine I, Vandenborne K, Hagers Y: Autonomic testing in patients with chronic fatigue syndrome. Am J Med 1998 105 (3A):22S-26S.
54. Schondorf R, Freeman R: The importance of orthostatic intolerance in the chronic fatigue syndrome. Am J Med Sci 1999, 317:117-123. This is a useful review evaluating the relation between orthostatic intolerance and CFS.
55. Wallace HL, Natelson B, Gause W, Hay J: Human herpes viruses in chronic fatigue syndrome. Clin Diagn Lab Immunol 1999, 6:216-223.
56. White PD, Thomas JM, Amess J, Crawford DH, Grover SA, Kangro HO, et al.: Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br J Psychiatry 1998, 173:475-481.
57. Vojdani A, Choppa PC, Tagle C, Andrin R, Samimi B, Lapp CW: Detection of mycoplasma genus and mycoplasma fermentans by PCR in patients with chronic fatigue syndrome. FEMS Immunol Med Microbiol 1998, 22:355-365. This important study has demonstrated the detection of Mycoplasma genus and Mycoplasma fermentans by polymerase chain reaction in patients with CFS. These results require independent confirmation in a large number of patients with CFS by other studies.
58. Evengard B, Nilsson CG, Lindh G, Lindquist L, Eneroth P, Fredrikson S, et al.: Chronic fatigue syndrome differs from fibromyalgia: no evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 1998, 78:153-155. In contrast to FM, levels of substance P were not elevated in the cerebrospinal fluid of patients with CFS.
59. Conti F, Pittoni V, Sacerdote P, Priori R, Meroni PL, Valesini G: Decreased immunoreactive beta-endorphin in mononuclear leukocytes from patients with chronic fatigue syndrome. Clin Exp Rheumatol 1998, 16:729-732.
60. Bell IR, Baldwin CM, Schwartz GE: Illness from low levels of environmental chemicals: Relevance to chronic fatigue syndrome and fibromyalgia. Am J Med 1998, 105 (3A):74S-82S.
61. MacHale SM, Cavanagh JT, Bennie J, Carrolls S, Goodwin GM, Lawrie SM: Diurnal variation of adrenocortical activity in chronic fatigue syndrome. Neuropsychobiology 1998, 38:213-217.
62. Whiteside TL, Friberg D: Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med 1998, 105 (3A):27S-34S.
63. Gupta S, Aggarwal S, Starr A: Increased production of interleukin-6 by adherent and non-adherent mononuclear cells during "natural fatigue" but not following "experimental fatigue" in patients with chronic fatigue syndrome. Int J Mol Med 1999, 3:209-213. Increased production of interleukin-6 by monocytes and lymhocytes has been demonstrated during "natural fatigue" but not following exercise-induced fatigue in patients with CFS.
64. See DM, Cimoch P, Chou S, Chang J, Tilles J: The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome. Integr Physiol Behav Sci 1998, 33:280-287.
65. Zhang Q, Zhou XD, Denny T, Ottenweller JE, Lange G, La Manca JJ, et al.: Changes in immune parameters seen in Gulf War veterans but not in civilians with chronic fatigue syndrome. Clin Diagn Lab Immunol 1999, 6:6-13. The data in this study do not support the hypothesis of immune dysfunction in the genesis of CFS for sporadic cases of CFS.
66. Natelson BH, La Manca JJ, Denny TN, Vladutiu A, Oleske J, Hill N, et al.: Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis. Am J Med 1998, 105 (3A):43S-49S.
67. Blackwood SK, MacHale SM, Power MJ, Goodwin GM, Lawrie SM: Effects of exercise on cognitive and motor function in chronic fatigue syndrome and depression. J Neurol Neurosurg Psychiatry 1998, 65:541-546.
68. Michiels V, Cluydts R, Fischler B: Attention and verbal learning in patients with chronic fatigue syndrome. J Int Neuropsychol Soc 1998, 4:456-466.
69. Krilov LR, Fisher M, Friedman SB, Reitman D, Mandel FS: Course and outcome of chronic fatigue in children and adolescents. Pediatrics 1998, 102:360-366. This study demonstrates that children and adolescents with CFS have a syndrome that is similar to that described in adults, but it presents earlier in the course of the illness and has a favorable outcome.
70. Marlin RG, Anchel H, Gibson JC, Goldberg WM, Swinton M: An evaluation of multidisciplinary intervention for chronic fatigue syndrome with long-term follow-up, and comparison with untreated controls. Am J Med 1998, 105 (3A):110S-114S.
71. Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J: Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999, 353:455-458. In some patients with CFS, low-dose hydrocortisone reduced fatigue levels in the short term.
72. McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, et al.: Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998, 280:1061-1066.
73. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA: Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999, 82:185-191. Four times as many patients with CFS responded to NADH treatment in contrast to placebo.
74. Warren G, McKendrick M, Peet M: The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA. Acta Neurol Scand 1999, 99:112-116.
75. Korszun A, Papadopoulos E, Demitrack M, Engleberg C, Crofford L: The relationship between tempormandibular disorders and stress-associated syndromes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 86:416-420.
76. Cimino R, Michelotti A, Stradi R, Farinaro C: Comparison of clinical and psychologic features of fibromyalgia and masticatory myofascial pain. J Orofac Pain 1998, 12:35-41.
77. Raphael KG, Marbach JJ, Gallagher RM, Dohrenwend BP: Myofascial TMD does not run in families. Pain 1999, 80:15-22. This important study has demonstrated that myofascial TMD does not run in families, nor do symptoms associated with a broad range of TMDs.
78. Lewis J, Tehan P: A blinded pilot study investigating the use of diagnostic ultrasound for detecting active myofascial trigger points. Pain 1999, 79:39-44.
79. Ferrari R, Leonard MS: Whiplash and temporomandibular disorders: a critical review. J Am Dent Assoc 1998, 129:1739-1745.
80. Ernst E, White AR: Acupuncture as a treatment for temporomandibular joint dysfunction. A systematic review of randomized trials. Arch Otolaryngol Head Neck Surg 1999, 125:269-272.
81. Vallon D, Nilner M, Soderfeldt B: Treatment outcome in patients with craniomandibular disorders of muscular origin: a 7-year follow-up. J Orofac Pain 1998, 12:210-218.
82. Heikkila H, Heikkila E, Eisemann M: Predictive factors for the outcome of a multidisciplinary pain rehabilitation programme on sick-leave and life satisfaction in patients with whiplash trauma and other myofascial pain: a follow-up study. Clin Rehabil 1998, 12:487-496.
83. Wheeler AH, Golkasian P, Gretz SS: A randomized double-blind, prospective pilot study of botulinum toxin injection for refractory unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23:1662-1666.
84. Davidoff RA: Trigger points and myofascial pain: toward understanding how they affect headaches. Cephalalgia 1998, 18:436-448.